Table 5 OS by cytogenetic risk
Good/intermediate | Poor | |||
|---|---|---|---|---|
Glasdegib + LDAC | LDAC alone | Glasdegib + LDAC | LDAC alone | |
Achieved CR | n = 12 | n = 0 | n = 3 | n = 1 |
Median OS, months (95% CI) | 30.4 (14.5–N/E) | – | 8.8 (7.4–12.4) | 12.9 (N/E–N/E) |
Survival probability, % (95% CI) | ||||
6 months | 100 (100–100) | – | 100 (100–100) | 100 (100–100) |
12 months | 100 (100–100) | – | 33.3 (0.9–77.4) | 100 (100–100) |
Deaths, n (%) | ||||
Cause of death: disease under study | 7 (58.3) | – | 3 (100) | 1 (100) |
Did not achieve CR | n = 41 | n = 22 | n = 22 | n = 15 |
Median OS, months (95% CI) | 7.7 (3.5–11.1) | 5.3 (3.5–8.7) | 4.0 (1.9–4.7) | 1.8 (0.6–3.1) |
Survival probability, % (95% CI) | ||||
6 months | 60.7 (43.5–74.1) | 45.1 (23.2–64.8) | 29.0 (11.9–48.7) | 13.3 (2.2–34.6) |
12 months | 34.3 (19.9–49.2) | 10.0 (1.7–27.3) | 14.5 (3.6–32.5) | N/E (N/E–N/E) |
Deaths, n (%) | ||||
Cause of death: disease under study | 30 (73.2) | 15 (68.2) | 19 (86.4) | 13 (86.7) |